Hub : Traits :

Gout (self-reported)

225 significantly associated models · 62 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	2	26592429	28607344	19	1	6.0e-28	3.8e-28	1.00000	100	FNDC4
2	3	52174970	53623102	2	1	1.8e-09	1.6e-10	0.02980	88	SFMBT1
3	4	9370814	11156010	4	9	3.2e-70	2.9e-88	NaN	NaN	RP11-448G15.3 SLC2A9 WDR1
4	4	87655053	89947462	7	13	3.8e-123	1.5e-197	NaN	NaN	ABCG2 HERC6 NUDT9 PKD2 PPM1K RP11-10L7.1 SPP1
5	5	72171715	72675238	1	1	1.7e-08	1.7e-08	1.00000	100	TMEM171
6	6	25266147	26689223	3	1	1.1e-16	9.4e-20	0.00015	83	U91328.21
7	7	71935903	73738067	2	1	6.1e-12	5.0e-12	1.00000	100	MLXIPL
8	10	60712592	62185494	1	1	4.8e-11	6.6e-13	0.00367	84	SLC16A9
9	11	63305184	66262606	7	7	6.8e-26	4.5e-21	NaN	NaN	CCDC88B NRXN2 OVOL1 SLC22A11 SLC22A12 VEGFB
10	12	56776586	58705075	4	1	4.6e-13	1.2e-14	0.00738	88	INHBC
11	12	121820692	123326374	1	1	5.0e-10	1.0e-10	1.00000	100	MLXIP
12	15	75444033	76878362	1	1	6.4e-09	1.5e-06	0.58700	99	UBE2Q2
13	15	90385311	90891982	1	1	1.1e-08	1.1e-08	1.00000	100	IDH2
14	16	69112398	70669292	1	1	2.3e-07	6.1e-08	0.05250	87	WWP2

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	0.89	1	0	0.0	0.00	1.0e+00	FNDC4
Bipolar Disorder or Schizophrenia	1.02	1	0	0.0	0.00	1.0e+00	U91328.21
Depressed Affect (Nagel 2018)	0.95	1	0	0.0	0.00	1.0e+00	CCDC88B
Intelligence (Savage-Jansen 2018)	0.99	1	1	2.2	0.00	1.0e+00	SFMBT1
Neuroticism (Nagel 2018)	0.78	1	0	0.0	0.00	1.0e+00	SFMBT1
Schizophrenia (2018)	1.21	1	0	0.0	0.00	1.0e+00	MLXIP
Schizophrenia vs Biploar Disorder	1.27	1	0	0.0	0.00	1.0e+00	FNDC4
Worry (Nagel 2018)	1.10	2	0	0.0	0.00	1.0e+00	PKD2 SFMBT1
Crohns Disease (2017)	1.45	2	1	2.2	0.00	1.0e+00	CCDC88B FNDC4
Irritable Bowel Disease (IBD)	0.91	1	1	2.2	0.00	1.0e+00	FNDC4
Verbal and Numeric Reasoning (VNR)	1.17	2	0	0.0	0.00	1.0e+00	SFMBT1 WWP2
Breast Cancer	2.46	2	1	2.2	0.95	5.1e-02	ABCG2 PPM1K
Crohns Disease (2012)	1.56	2	0	0.0	0.00	1.0e+00	CCDC88B FNDC4
Fasting Glucose	3.00	1	1	2.2	0.00	1.0e+00	FNDC4
HDL Cholesterol	1.61	2	1	2.2	0.00	1.0e+00	INHBC MLXIPL
LDL Cholesterol	1.14	1	0	0.0	0.00	1.0e+00	FNDC4
Primary Biliary Cirrhosis	1.44	1	0	0.0	0.00	1.0e+00	CCDC88B
Triglycerides	14.79	3	3	6.7	0.00	1.0e+00	FNDC4 INHBC MLXIPL
Ulcerative Colitis	1.14	1	0	0.0	0.00	1.0e+00	SFMBT1
Blood Eosinophil Count	0.88	3	2	4.4	0.00	1.0e+00	MLXIPL OVOL1 WWP2
Blood Platelet Count	1.89	8	4	8.9	0.71	5.0e-02	FNDC4 INHBC MLXIP MLXIPL NUDT9 OVOL1 SLC2A9 UBE2Q2
Blood Red Count	1.01	7	5	11.1	-0.24	6.1e-01	FNDC4 INHBC MLXIP SFMBT1 SLC2A9 UBE2Q2 WWP2
Blood White Count	1.72	4	2	4.4	0.92	7.8e-02	FNDC4 MLXIPL SLC16A9 WWP2
Heel T-Score	1.82	8	4	8.9	0.60	8.5e-02	ABCG2 CCDC88B OVOL1 PKD2 PPM1K SLC16A9 SPP1 TMEM171
BMI	2.02	9	8	17.8	-0.75	1.2e-02	ABCG2 FNDC4 MLXIP MLXIPL NRXN2 PPM1K RP11-10L7.1 SLC22A12 WWP2
Height	1.14	11	7	15.6	-0.60	4.1e-02	FNDC4 MLXIP MLXIPL NUDT9 OVOL1 SLC16A9 SLC2A9 SPP1 TMEM171 WDR1 WWP2
Waist Hip Ratio (WHR)	1.03	2	2	4.4	0.00	1.0e+00	MLXIP MLXIPL
Systolic Blood Pressure	0.98	4	0	0.0	0.96	4.2e-02	FNDC4 MLXIP OVOL1 SLC16A9
Smoking Status	1.03	2	0	0.0	0.00	1.0e+00	CCDC88B NRXN2
Allergy or Eczema	1.37	3	2	4.4	0.00	1.0e+00	FNDC4 MLXIP OVOL1
Cardiovascular Disease	1.40	4	1	2.2	1.00	2.5e-03	CCDC88B FNDC4 MLXIPL OVOL1
Hypothyroidism (self reported)	1.75	3	1	2.2	0.00	1.0e+00	CCDC88B MLXIP PKD2
Type 2 Diabetes (T2D) (2018)	1.84	2	1	2.2	0.00	1.0e+00	FNDC4 WWP2
Lung FEV1/FVC ratio	0.61	2	1	2.2	0.00	1.0e+00	SLC2A9 WDR1
Lung FVC	1.04	2	1	2.2	0.00	1.0e+00	SLC2A9 WWP2
Neuroticism	0.82	1	0	0.0	0.00	1.0e+00	SFMBT1
Chronotype (morning person)	0.69	1	0	0.0	0.00	1.0e+00	WWP2
Hair Pigment	0.13	4	0	0.0	0.27	7.3e-01	FNDC4 INHBC MLXIPL OVOL1
Tanning	0.33	2	1	2.2	0.00	1.0e+00	FNDC4 MLXIPL
Hand grip strength (left)	1.19	1	0	0.0	0.00	1.0e+00	WWP2
Number of treatments/medications taken	1.46	2	0	0.0	0.00	1.0e+00	FNDC4 OVOL1
Sensitivity / hurt feelings	0.89	1	0	0.0	0.00	1.0e+00	U91328.21
Relative age of first facial hair	1.38	2	1	2.2	0.00	1.0e+00	FNDC4 OVOL1
Medication: Metformin	1.09	1	1	2.2	0.00	1.0e+00	FNDC4
Diabetes (father)	1.34	1	0	0.0	0.00	1.0e+00	FNDC4
Diabetes (mother)	1.56	1	0	0.0	0.00	1.0e+00	FNDC4
Pack years adult smoking proportion	1.16	1	0	0.0	0.00	1.0e+00	SFMBT1
Impedance of leg (right)	1.50	5	2	4.4	0.88	4.7e-02	FNDC4 MLXIP MLXIPL PPM1K SPP1
Leg fat-free mass (left)	1.94	7	3	6.7	-0.86	1.2e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Trunk fat percentage	1.22	4	2	4.4	-0.52	4.8e-01	MLXIP NRXN2 RP11-10L7.1 WWP2
Hand grip strength (right)	0.89	1	0	0.0	0.00	1.0e+00	WWP2
Fed-up feelings	1.28	1	0	0.0	0.00	1.0e+00	CCDC88B
Taking other prescription medications	1.63	1	0	0.0	0.00	1.0e+00	CCDC88B
Age when periods started (menarche)	1.14	1	1	2.2	0.00	1.0e+00	WWP2
Heel bone mineral density (BMD) T-score, automated (left)	1.49	3	1	2.2	0.00	1.0e+00	OVOL1 PKD2 SPP1
High blood pressure	1.14	2	0	0.0	0.00	1.0e+00	CCDC88B OVOL1
Hayfever, allergic rhinitis or eczema	1.51	3	1	2.2	0.00	1.0e+00	MLXIP OVOL1 U91328.21
Medication: Levothyroxine sodium	1.44	1	0	0.0	0.00	1.0e+00	CCDC88B
Sitting height	1.75	7	6	13.3	-0.93	2.0e-03	FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21 WWP2
Body mass index (BMI)	1.75	7	2	4.4	-0.75	5.1e-02	ABCG2 FNDC4 MLXIP NRXN2 PPM1K SLC22A12 WWP2
Impedance of leg (left)	1.66	6	3	6.7	0.68	1.4e-01	FNDC4 MLXIP MLXIPL PPM1K SLC2A9 SPP1
Leg predicted mass (left)	1.93	7	3	6.7	-0.86	1.2e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Trunk fat mass	1.39	5	2	4.4	-0.80	1.1e-01	ABCG2 MLXIP NRXN2 RP11-10L7.1 WWP2
Waist circumference	1.59	6	2	4.4	-0.82	4.6e-02	ABCG2 FNDC4 MLXIP PPM1K RP11-10L7.1 WWP2
Nervous feelings	1.07	1	0	0.0	0.00	1.0e+00	SFMBT1
Forced vital capacity (FVC)	1.15	3	1	2.2	0.00	1.0e+00	PKD2 PPM1K WWP2
Heel bone mineral density (BMD) T-score, automated (right)	1.50	4	1	2.2	0.98	1.6e-02	OVOL1 PKD2 PPM1K SPP1
Qualifications: None of the above	0.77	1	0	0.0	0.00	1.0e+00	SFMBT1
Heart attack	1.03	1	0	0.0	0.00	1.0e+00	INHBC
Allergy	1.21	2	1	2.2	0.00	1.0e+00	MLXIP OVOL1
Diabetes (self-reported)	1.59	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Simvastatin	1.90	1	1	2.2	0.00	1.0e+00	FNDC4
Fluid intelligence score	1.05	2	0	0.0	0.00	1.0e+00	SFMBT1 WWP2
Neuroticism score	0.88	1	0	0.0	0.00	1.0e+00	SFMBT1
Weight	1.82	6	3	6.7	-0.91	1.2e-02	ABCG2 FNDC4 MLXIP MLXIPL NRXN2 U91328.21
Impedance of arm (right)	1.90	3	2	4.4	0.00	1.0e+00	FNDC4 MLXIPL SLC2A9
Arm fat percentage (right)	1.47	4	2	4.4	0.96	3.9e-02	MLXIP PPM1K RP11-10L7.1 WWP2
Trunk fat-free mass	2.21	7	5	11.1	-0.87	1.1e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Hip circumference	2.11	6	4	8.9	-0.79	6.3e-02	ABCG2 FNDC4 MLXIP MLXIPL NRXN2 WWP2
Alcohol intake versus 10 years previously	2.13	1	1	2.2	0.00	1.0e+00	FNDC4
Forced expiratory volume in 1-second (FEV1)	0.96	3	1	2.2	0.00	1.0e+00	PKD2 PPM1K WWP2
Pulse rate	1.32	1	1	2.2	0.00	1.0e+00	FNDC4
Serious illness, injury or assault of a close relative in last 2 years	1.58	1	0	0.0	0.00	1.0e+00	WWP2
Asthma	0.78	1	0	0.0	0.00	1.0e+00	U91328.21
Medication: Cholesterol lowering	1.81	1	1	2.2	0.00	1.0e+00	FNDC4
Illnesses of mother	2.07	1	0	0.0	0.00	1.0e+00	WDR1
Forced expiratory volume in 1-second (FEV1), Best measure	0.92	2	1	2.2	0.00	1.0e+00	U91328.21 WWP2
Impedance of arm (left)	2.03	3	2	4.4	0.00	1.0e+00	FNDC4 MLXIPL SLC2A9
Arm fat mass (right)	1.60	7	2	4.4	-0.76	4.8e-02	ABCG2 FNDC4 MLXIP NRXN2 PPM1K RP11-10L7.1 WWP2
Trunk predicted mass	2.21	7	5	11.1	-0.86	1.2e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Standing height	1.36	9	5	11.1	-0.67	3.6e-02	FNDC4 MLXIP NUDT9 SLC16A9 SLC2A9 SPP1 TMEM171 U91328.21 WWP2
Peak expiratory flow (PEF)	0.70	1	0	0.0	0.00	1.0e+00	WWP2
Headache pain in last month	0.99	1	0	0.0	0.00	1.0e+00	NUDT9
Medication for cholesterol, blood pressure or diabetes	1.25	1	0	0.0	0.00	1.0e+00	FNDC4
Hypothyroidism/myxoedema (self-reported)	1.52	1	0	0.0	0.00	1.0e+00	CCDC88B
Medication: Amlodipine	1.39	1	0	0.0	0.00	1.0e+00	OVOL1
High blood pressure (siblings)	1.02	1	0	0.0	0.00	1.0e+00	FNDC4
Forced vital capacity (FVC), Best measure	1.18	2	1	2.2	0.00	1.0e+00	SLC16A9 WWP2
Body fat percentage	1.32	6	2	4.4	-0.70	1.2e-01	ABCG2 MLXIP NRXN2 PPM1K RP11-10L7.1 WWP2
Leg fat percentage (right)	1.49	7	2	4.4	-0.76	4.8e-02	ABCG2 MLXIP NRXN2 PPM1K RP11-10L7.1 SLC22A12 WWP2
Arm fat-free mass (right)	2.22	7	4	8.9	-0.87	1.2e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Comparative body size at age 10	1.09	2	0	0.0	0.00	1.0e+00	MLXIP OVOL1
Medication: Allopurinol	44.90	27	21	46.7	1.00	4.0e-43	ABCG2 CCDC88B FNDC4 HERC6 IDH2 INHBC MLXIP MLXIPL NRXN2 NUDT9 OVOL1 PKD2 PPM1K RP11-10L7.1 RP11-448G15.3 SFMBT1 SLC16A9 SLC22A11 SLC22A12 SLC2A9 SPP1 TMEM171 U91328.21 UBE2Q2 VEGFB WDR1 WWP2
Whole body fat mass	1.52	6	2	4.4	-0.78	6.7e-02	ABCG2 MLXIP NRXN2 PPM1K RP11-10L7.1 WWP2
Leg fat mass (right)	1.69	8	2	4.4	-0.81	1.5e-02	ABCG2 FNDC4 MLXIP NRXN2 PPM1K RP11-10L7.1 SLC22A12 WWP2
Arm predicted mass (right)	2.21	7	4	8.9	-0.86	1.3e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Pulse rate, automated reading	1.90	3	1	2.2	0.00	1.0e+00	FNDC4 MLXIPL WWP2
Alcohol intake frequency.	2.98	4	1	2.2	0.97	3.2e-02	FNDC4 MLXIPL UBE2Q2 WWP2
Comparative height size at age 10	1.43	6	3	6.7	-0.70	8.0e-02	FNDC4 MLXIP SLC16A9 SLC2A9 TMEM171 U91328.21
Number of full sisters	1.04	1	0	0.0	0.00	1.0e+00	SLC2A9
Suffer from 'nerves'	1.23	1	0	0.0	0.00	1.0e+00	SFMBT1
Supplements: Vitamin C	0.86	1	0	0.0	0.00	1.0e+00	WWP2
Hypertension (Self-reported)	1.17	2	0	0.0	0.00	1.0e+00	CCDC88B OVOL1
Forced expiratory volume in 1-second (FEV1), predicted	0.95	1	0	0.0	0.00	1.0e+00	SLC16A9
Whole body fat-free mass	2.10	7	4	8.9	-0.86	1.2e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Leg fat-free mass (right)	1.84	7	3	6.7	-0.86	1.2e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Arm fat percentage (left)	1.63	5	2	4.4	-0.69	2.0e-01	ABCG2 MLXIP PPM1K RP11-10L7.1 WWP2
Mood swings	1.50	1	0	0.0	0.00	1.0e+00	SFMBT1
Diabetes diagnosed by doctor	1.78	2	1	2.2	0.00	1.0e+00	FNDC4 WWP2
Qualifications: nursing, teaching	1.27	1	0	0.0	0.00	1.0e+00	SFMBT1
Medication for cholesterol	1.39	1	1	2.2	0.00	1.0e+00	FNDC4
Back pain experienced in last month	1.25	1	0	0.0	0.00	1.0e+00	NUDT9
Osteoporosis (self-reported)	1.51	1	0	0.0	0.00	1.0e+00	SPP1
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.11	1	0	0.0	0.00	1.0e+00	WWP2
Whole body water mass	2.14	7	4	8.9	-0.86	1.3e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Leg predicted mass (right)	1.85	7	3	6.7	-0.86	1.2e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Arm fat mass (left)	1.65	7	2	4.4	-0.76	4.9e-02	ABCG2 FNDC4 MLXIP NRXN2 PPM1K RP11-10L7.1 WWP2
Number of self-reported non-cancer illnesses	1.95	2	1	2.2	0.00	1.0e+00	CCDC88B FNDC4
Medication: Blood pressure	1.47	1	0	0.0	0.00	1.0e+00	OVOL1
Pain type(s) experienced in last month: Hip pain	2.19	1	0	0.0	0.00	1.0e+00	MLXIP
High cholesterol (Self-reported)	3.56	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Lisinopril	1.05	1	0	0.0	0.00	1.0e+00	MLXIP
Medication: Atorvastatin	2.30	1	1	2.2	0.00	1.0e+00	FNDC4
Ever smoked	1.73	2	0	0.0	0.00	1.0e+00	NRXN2 SLC22A12
Basal metabolic rate	2.02	7	4	8.9	-0.88	8.9e-03	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Leg fat percentage (left)	1.38	7	2	4.4	-0.77	4.4e-02	ABCG2 MLXIP NRXN2 PPM1K RP11-10L7.1 SLC22A12 WWP2
Arm fat-free mass (left)	2.07	7	4	8.9	-0.86	1.3e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Diastolic blood pressure, automated reading	0.76	2	0	0.0	0.00	1.0e+00	MLXIP OVOL1
Vascular/heart problems diagnosed by doctor	1.12	3	0	0.0	0.00	1.0e+00	CCDC88B MLXIP OVOL1
Cholesterol lowering medication	2.10	1	1	2.2	0.00	1.0e+00	FNDC4
Basal cell carcinoma (self-reported)	1.05	1	0	0.0	0.00	1.0e+00	CCDC88B
Heart attack/myocardial infarction (self-reported)	1.07	1	0	0.0	0.00	1.0e+00	INHBC
Pack years of smoking	1.13	1	0	0.0	0.00	1.0e+00	SFMBT1
Impedance of whole body	1.96	6	2	4.4	0.76	7.9e-02	ABCG2 FNDC4 MLXIPL PPM1K SLC2A9 SPP1
Leg fat mass (left)	1.65	7	2	4.4	-0.81	2.7e-02	ABCG2 FNDC4 MLXIP NRXN2 PPM1K RP11-10L7.1 WWP2
Arm predicted mass (left)	2.14	7	4	8.9	-0.87	1.0e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	9	0.258	1.5
GTEx	Adipose Visceral Omentum	8	0.393	1.6
GTEx	Adrenal Gland	2	0.137	1.4
GTEx	Artery Aorta	5	0.168	1.4
GTEx	Artery Coronary	4	0.338	1.5
GTEx	Artery Tibial	9	0.239	1.4
GTEx	Brain Caudate basal ganglia	0	0.000	1.2
GTEx	Brain Cerebellar Hemisphere	1	0.067	1.3
GTEx	Brain Cerebellum	1	0.050	1.4
GTEx	Brain Cortex	1	0.097	1.3
GTEx	Brain Frontal Cortex BA9	0	0.000	1.3
GTEx	Brain Hippocampus	0	0.000	1.3
GTEx	Brain Hypothalamus	0	0.000	1.3
GTEx	Brain Nucleus accumbens basal ganglia	1	0.116	1.3
GTEx	Brain Putamen basal ganglia	0	0.000	1.3
GTEx	Breast Mammary Tissue	2	0.101	1.4
GTEx	Breast Mammary Tissue (Male)	2	0.168	1.3
GTEx	Breast Mammary Tissue (Female)	1	0.061	1.4
GTEx	Cells EBV-transformed lymphocytes	2	0.141	1.4
GTEx	Cells Transformed fibroblasts	6	0.143	1.3
GTEx	Colon Sigmoid	3	0.205	1.5
GTEx	Colon Transverse	6	0.291	1.5
GTEx	Esophagus Gastroesophageal Junction	2	0.138	1.4
GTEx	Esophagus Mucosa	6	0.181	1.5
GTEx	Esophagus Muscularis	5	0.155	1.5
GTEx	Heart Atrial Appendage	0	0.000	1.3
GTEx	Heart Left Ventricle	1	0.065	1.4
GTEx	Liver	1	0.139	1.5
GTEx	Lung	5	0.174	1.4
GTEx	Muscle Skeletal	5	0.173	1.4
GTEx	Nerve Tibial	9	0.208	1.4
GTEx	Ovary	1	0.110	1.4
GTEx	Pancreas	2	0.123	1.3
GTEx	Pituitary	1	0.090	1.3
GTEx	Prostate	1	0.120	1.4
GTEx	Skin Not Sun Exposed Suprapubic	4	0.163	1.4
GTEx	Skin Sun Exposed Lower leg	5	0.137	1.4
GTEx	Small Intestine Terminal Ileum	1	0.217	1.5
GTEx	Spleen	2	0.142	1.4
GTEx	Stomach	0	0.000	1.3
GTEx	Testis	5	0.158	1.4
GTEx	Thyroid	7	0.175	1.4
GTEx	Uterus	0	0.000	1.3
GTEx	Vagina	1	0.157	1.5
GTEx	Whole Blood	4	0.201	1.5
METSIM	Adipose	7	0.152	1.4
NTR	Blood	2	0.083	1.4
ROSMAP	Brain Pre-frontal Cortex	10	0.228	1.4
YFS	Blood	4	0.087	1.3
CommonMind	Brain Pre-frontal Cortex	7	0.130	1.3
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	2	0.121	1.3
The Cancer Genome Atlas	Breast Invasive Carcinoma	10	0.227	1.4
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.273	1.4
The Cancer Genome Atlas	Colon Adenocarcinoma	2	0.097	1.3
The Cancer Genome Atlas	Esophageal Carcinoma	1	0.146	1.4
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.4
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	3	0.110	1.6
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	10	0.244	1.4
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	3	0.146	1.4
The Cancer Genome Atlas	Brain Lower Grade Glioma	3	0.070	1.3
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	1	0.090	1.4
The Cancer Genome Atlas	Lung Adenocarcinoma	2	0.068	1.2
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	3	0.188	1.4
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	2	0.120	1.4
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.3
The Cancer Genome Atlas	Prostate Adenocarcinoma	7	0.151	1.3
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.3
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.2
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.4
The Cancer Genome Atlas	Stomach Adenocarcinoma	2	0.119	1.3
The Cancer Genome Atlas	Testicular Germ Cell Tumors	0	0.000	1.4
The Cancer Genome Atlas	Thyroid Carcinoma	8	0.155	1.4
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.3